Pyrrolo and imidazo pyridine compounds, protein kinase inhibitors, therapeutic applications
Summary
EPO published patent EP3697787A1 for HK inno.N Corporation covering pyrrolo[2,3-b]pyridine and imidazo[4,5-b]pyridine compounds as protein kinase inhibitors for therapeutic applications including cancer, metabolic, and neurological disorders.
What changed
EPO published patent EP3697787A1 granting HK inno.N Corporation exclusive rights to pyrrolo[2,3-b]pyridine and imidazo[4,5-b]pyridine compounds as protein kinase inhibitors. The patent covers therapeutic applications including A61P 3/00 (metabolic disorders), A61P 25/00 (neurological disorders), and A61P 35/00 (cancer). The patent is designated across 31 European states including DE, FR, GB, IT, ES, NL, BE, and SE.
For pharmaceutical companies developing kinase inhibitor therapies, this patent establishes protected compound classes that may require licensing agreements or design-around strategies. Competitors in the targeted therapeutic areas should review their compound pipelines for potential overlap with the protected chemical structures.
What to do next
- Monitor for updates
- Assess freedom-to-operate implications for competing kinase inhibitor development
- Evaluate potential licensing opportunities
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PYRROLO[2,3-B]PYRIDINE AND IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AS A PROTEIN KINASE INHIBITORS
Publication EP3697787A1 Kind: A1 Apr 01, 2026
Applicants
HK inno.N Corporation
Inventors
LEE, Hyuk Woo, JI, Mi Kyung, KIM, Seung Chan, YU, Ha Na, JUNG, Soo Yeon, PARK, Ji-Yeon, LEE, Ye-Lim, LEE, Ho-Youl, KI, So Young, KIM, Dongkyu, KIM, Myeongjoong
IPC Classifications
C07D 471/04 20060101AFI20221110BHEP A61K 31/437 20060101ALI20221110BHEP A61K 31/519 20060101ALI20221110BHEP C07D 487/04 20060101ALI20221110BHEP C07D 201/00 20060101ALI20221110BHEP A61P 3/00 20060101ALI20221110BHEP A61P 25/00 20060101ALI20221110BHEP A61P 35/00 20060101ALI20221110BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.